The Discovery Team
We have a small, dedicated, cross-functional team and feel strongly about maintaining scientific integrity. The Enabled Therapeutics espirit de corps is rooted in mutual respect and trust that has been cultivated over years of shared effort. We all wear many hats – proudly.
The Board
Enabled Therapeutics has been fortunate in the composition of its Board of Directors. Relying initially on two hapless founders, Enabled Therapeutics was mercifully introduced by friends to our board members. Possessed of extraordinary and fortuitously-apt skills for an endeavor like Enabled Therapeutics their accession to the Board provided encouragement to a team in need of a little validation and added decades of applicable experience to Enabled Therapeutics’ managerial team.
The Advisory Board
A tiny company, a remarkable discovery, and a lot to do. Mercaptor presented some interesting problems. And not the kind familiar to scientists. One such problem was in engaging the world and communicating our story; another, related, but a more existential problem, was in finding money. We needed help. People to show us a way, without ignoring some founding principles: Avoid reliance on the sclerotic, inefficient approach to drug development common in the modern pharmaceutical industry.
Kim R. Tsuchimoto | Advisor to the BOD
Ms. Tsuchimoto co-founded Mercaptor Discoveries Inc. and is our part-time Chief Financial Officer. Ms. Tsuchimoto is also the Chief Financial Officer of Monopar Therapeutics since
Ralph O’Rear | Advisor to the BOD
Ralph O’Rear provides Mercaptor strategic advice with regards to general business strategy, facilities, and operations. After 18 years at the Buck Institute for Research on Aging
Dr. Adriano Aguzzi, MD, PhD
Dr. Adriano Aguzzi, MD, PhD, is heading up the formation of Mercaptor’s Scientific Advisory Board (SAB). Dr. Aguzzi is a world-renowned neuropathologist, whose research has garnered